Table 1.
Baseline Characteristics of Participants in the Immunogenicity Substudy of the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE)
| Participants, No. (%) | |||||||
| Characteristic | Total (N = 506) | Any Baseline Malaria Result (n = 499) |
Malaria Negative at Baseline (n = 426) |
Malaria Positive at Baseline (n = 73) |
Parasite Density |
||
| Low (0.1 to <10/mL) (n = 31) | Moderate (10–200/mL) (n = 29) | High (>200/mL) (n = 13) | |||||
| Sex | |||||||
| Male | 293 (57.9) | 288 (57.7) | 230 (54.0) | 58 (79.4) | 29 (93.6) | 20 (69.0) | 9 (30.8) |
| Female | 213 (42.1) | 211 (42.3) | 196 (46.0) | 15 (20.6) | 2 (6.4) | 9 (31.0) | 4 (69.2) |
| Age | |||||||
| 18–50 y | 468 (92.5) | 461 (92.4) | 392 (92.0) | 69 (94.5) | 30 (96.8) | 28 (96.6) | 11 (84.6) |
| >50 y | 38 (7.5) | 38 (7.6) | 34 (8.0) | 4 (5.5) | 1 (3.2) | 1 (3.4) | 2 (15.4) |
| Positive for Ebola at baseline (before vaccination) | |||||||
| GP-ELISA | |||||||
| No | 427 (84.4) | 421 (84.4) | 366 (85.9) | 55 (75.3) | 27 (87.1) | 20 (69.0) | 8 (61.5) |
| Yes | 76 (15.0) | 75 (15.0) | 58 (13.6) | 17 (23.3) | 4 (12.9) | 8 (27.6) | 5 (38.5) |
| Missinga | 3 (0.6) | 3 (0.6) | 2 (0.5) | 1 (1.4) | 0 (0) | 1 (3.4) | 0 (0) |
| PRNT | |||||||
| No | 434 (85.8) | 427 (85.6) | 365 (85.7) | 62 (84.9) | 27 (87.1) | 24 (82.8) | 11 (84.6) |
| Yes | 4 (0.9) | 4 (0.8) | 3 (0.7) | 1 (1.4) | 0 (0) | 1 (3.5) | 0 (0) |
| Missinga | 68 (13.4) | 68 (13.6) | 58 (13.6) | 10 (13.7) | 4 (12.9) | 4 (13.8) | 2 (15.4) |
Note: Table includes participants with ≥1 evaluable result from a sample obtained within the allowed postvaccination time windows.
Abbreviations: GP-ELISA, glycoprotein enzyme-linked immunosorbent assay; PRNT, plaque reduction neutralization test.
aA baseline specimen was not available for 3 participants. An additional 65 participants had indeterminate results from baseline PRNT testing.